Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: Clinicopathological correlations

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1777-1782

  Gershtein, Elena S ^a   Scherbakov, Alexander M ^a   Shatskaya, Valentina A ^a   Kushlinsky, Nicolai E ^a   Krasil'nikov, Mikhail A ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Breast cancer; ELISA; Mammary gland; Phosphatidylinositol 3 kinase; Phospho Akt1; Western blotting

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN ANTIBODY; PROTEIN KINASE B; PROTEIN P85; PROTEIN P85 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; BREAST CANCER; CANCER GRADING; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; BLOTTING, WESTERN; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 34250743030     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Fry MJ: Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 3: 304-312, 2001.
2. El-Deiry WS: Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol 3: E71-E73, 2001.
3. Kumar R and Hung MC: Signaling intricacies take center stage in cancer cells. Cancer Res 65: 2511-2515, 2005.
4. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998, 2003.
5. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB and Bast RC Jr: Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signalling. J Biol Chem 280: 2092-2104, 2005.
6. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824, 2001.
7. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB and Stoica A: Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17: 818-830, 2003.
8. Jordan NJ, Gee JM, Barrow D, Wakeling AE and Nicholson RI: Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 87: 167-180, 2004.
9. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV and Cheng JQ: Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61: 5985-5991, 2001.
10. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212, 2003.
11. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE and Dowsett M: Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9: 524S-532S, 2003.
12. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L and Fan Z: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2: 353-360, 2003.
13. Crowder RJ and Ellis MJ: Treating breast cancer through novel inhibitors of the phosphatidylinositol 3′-kinase pathway. Breast Cancer Res 7: 212-214, 2005.
14. Gershtein ES, Shatskaya VA, Ermilova VD, Kushlinsky NE and Krasil'nikov MA: Phosphatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta 287: 59-67, 1999.
15. Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M and Winters ZE: Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. Eur J Cancer 41: 1017-1025, 2005.
16. Perez-Tenorio G, Stal O and members of the Southeast Sweden Breast Cancer Group: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545, 2002.
17. Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L and Rutqvist LE: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5: R37-R44, 2003.
18. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A and Bartlett JM: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-146, 2005.
19. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW and Baba HA: Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17: 15-21, 2004.
20. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, Kimmig R, Schmid KW and Baba HA: High expression of focal adheson kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res 7: R194-R203, 2005.
21. Cicenas J, Urban P, Vuaroqueaux V et al: Increased level of phosporylated Akt measured by chemiluminiscence-linked immunisorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 7: R394-R401, 2005.
22. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF and Ellis IO: The role of PTEN and its signalling pathways, including AKT, in breast cancer: an assessment of relationships with other prognostic factors and with outcome. J Pathol 204: 93-100, 2004.
23. Zhou X, Tan M, Stone Hawthorne V et al: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788, 2004.
24. Bellacosa A, de Feo D, Godwin AK et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280-285, 1995.
25. Zinda MJ, Johnson MA, Paul JD et al: AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 7: 2475-2479, 2001.
26. Nakatani K, Thompson DA, Barthel A et al: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528-21532, 1999.
27. Amundadottirl L and Leder P: Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16: 737-746, 1998.
28. Cui X, Zhang P, Deng W et al: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/ mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17: 575-588, 2003.